



# CAPA eNewsletter



CHINESE AMERICAN PATHOLOGISTS ASSOCIATION

~ 全美华人病理学会 ~

VOLUME 1 ISSUE 4 2015

## In this issue:

The CAPA Annual Report 2015-2016	P1-P6
CAPA-Participation of CSP 2015	P1, P7-P8
Introducing CAPA Pathologists/Scientists	P7
Acknowledgements and Advertisements for CAPA Sponsors	P8-P9

### Editing Team:

Huan-You Wang  
 Jun Zhang  
 Fan Chen  
 Jie Song  
 Zenggang Pan  
 Kar-Ming Fung  
 Longwen Chen  
 Yajue Huang  
 Huimiao Jiang

### Design:


Fan Chen



## The CAPA Annual Report 2015-2016

**D**ear CAPA friends:  
 It was my great honor to serve as the Chinese American Pathologists Association (CAPA) President in 2015. It was a very busy, productive, and rewarding year in my professional career, and it certainly was a great year for CAPA! Together, we have accomplished the goals that I announced at the last CAPA Annual Business Meeting in Boston. Congratulations and thanks to all CAPA members, especially those of you who have been actively involved in and contributed to this great pathology community! Because of your strong support, dedication and contributions, CAPA achieved many goals and reached many new milestones in 2015, such as 1) establishing functional CAPA Subcommittees; 2) hosting the first CAPA Diagnostic Pathology Course in New York City; 3) co-organizing the first CAPA-Beijing Diagnostic Pathology Course in Beijing; 4) participating in the Chinese Society of Pathology (CSP) 2015 Annual Meeting in Kunming; 5) participating in the 9<sup>th</sup> AP-IAP Meeting in Brisbane, Australia; 6) publishing quarterly CAPA eNewsletters; 7) refining the CAPA website and increasing the number of website visits; 8) authoring a special section of review articles based on the CAPA Diagnostic Pathology Course for the *Archives of Pathology and Laboratory Medicine*; 9) preparing for the first CAPA Companion Meeting at the 2016 CAP meeting; 10) recruiting many more members, including many lifetime members; 11) attracting

more sponsors to make CAPA more financially stable and healthier than ever; 12) improving management of the CAPA pre-existing accounts and completing an auditing process; and 13) creating two new CAPA awards - CAPA Honorary Award and CAPA Member of the Year Award, et al. The details are highlighted below:



### 1. Establishment of Functional CAPA Subcommittees

The establishment of the CAPA functional Subcommittees was the key step to successfully implementing ambitious goals. In addition to the Executive Committee (EC), seven Subcommittees were formed, including the Education Committee, Membership Committee, Nomination and Awards Committee, Publication and Website Committee, Finance Committee, Career Development/Academic Affairs Committee, and Practicing Pathologists Committee. Please go to the CAPA website for a list of the members of each subcommittee. The EC members and the chair and co-chair(s) of each subcommittee have met regularly by teleconference to plan and monitor the progress of each project and to resolve potential issues and concerns. The collective team efforts and wisdom have proven very effective!

(Cont'd on Page 2)

## CAPA Participation of CSP 2015

Submitted by Marilyn Bui, Yun Gong and Beiyun Chen

**T**he 21<sup>st</sup> Congress of Chinese Society of Pathology and 5<sup>th</sup> Annual Meeting of Chinese Pathologists were successfully held from Nov 5 to 8 in Kunming, Yunnan Province. The meeting had various tracks including subspecialty training, platform presentation and unknown case discussion. It was well attended by over 1500 registered attendees.

(Cont'd on Page 7)





## The CAPA Annual Report 2015-2016 (Cont'd)

(Cont'd from Page 1)

### 2. Education Programs

#### A. The First CAPA Diagnostic Course in New York

The first CAPA Diagnostic Pathology Course, "Best Practices in Diagnostic Immunohistochemistry for Both Surgical Pathology and Cytopathology," was successfully held from Saturday, August 22, to Monday, August 24, 2015, at the Sheraton LaGuardia East Hotel, Flushing, New York. The conference was approved by the CAPA EC and organized by Fan Lin, Lanjing Zhang, Lizhen Gui, Zongming Chen, Marilyn Bui, Huamin Wang, Fang Fan, and Jim Zhai. Over 130 practicing Chinese pathologists, fellows, and residents from different states attended this exciting and successful event!

This two-day course included didactic lectures and case-based presentations of diagnostically challenging cases in the fields of surgical pathology and cytopathology. It allowed practicing anatomic pathologists to become proficient in the application of diagnostic IHC in different subspecialties. The conference, presented by 28 national experts in the field of IHC, provided in-depth discussions on standardization of diagnostic IHC, newly described IHC markers, and implementation of best practices in diagnostic IHC. It addressed questions that practicing pathologists encounter in day-to-day practice and helped residents and fellows with their specialty board exam preparations.

This was another milestone for CAPA, but it would not have happened without the overwhelming support from the following people. Very special thanks to all of you!

#### **Course Faculty:**

Marilyn Bui (Moffitt Cancer Center), Guoping Cai (Yale University), Beiyun Chen (Mayo Clinic), Longwen Chen (Mayo Clinic), Zongming Chen (Geisinger Medical Center), Fang-Ming Deng (NYU), Fang Fan (University of Kansas), Yun Gong (UT MD Anderson Cancer Center), Lizhen Gui (Northwest Arkansas Pathology), Yajue Huang (Mayo Clinic), Pei Hui (Yale University), Fan Lin (Geisinger Medical Center), Haiyan Liu (Geisinger Medical Center), Yan Peng (UT Southwestern Medical Center), Xiaohua Qian (Brigham and Women's Hospital/

Harvard Medical School), Steven S. Shen (Houston Methodist Hospital/Cornell University), Ping Tang (University of Rochester), Beverly Wang (UC Irvine), Hanlin Wang (UCLA), Huamin Wang (UT MD Anderson Cancer Center), Huan-You Wang (UCSD), Chin-Lee Wu (MGH/Harvard Medical School), Ximing Yang (Northwestern University), Haodong Xu (UCLA), Limin Yu (Diagnostic Pathology Medical Group Inc., Sacramento, CA), Lanjing Zhang (Princeton HealthCare System/Rutgers University), Xinmin Zhang (Temple University), Jim Zhai (Mayo Clinic), and Youli Zu (Houston Methodist Hospital/Cornell University)

#### **Accreditation:**

Special thanks to Princeton HealthCare System. This activity was planned and implemented in accordance with the accreditation requirements and policies of the Medical Society of New Jersey (MSNJ) through the joint providership of Princeton HealthCare System and CAPA. Princeton HealthCare System is accredited by MSNJ to provide continuing medical education for physicians.

#### **Contributors:**

Huihong Xu was a great help to Lizhen Gui in checking and recording the number of people registering for this course at the CAPA website.

On the conference morning, many volunteers, including Huihong Xu, Fan Chen, Peihong Hsu, Yihui Wu, Min Guo, Peisha Yan, Bihong Zhao, Songlin Liang, Jinhong Li and Shuan Li, spent hours at the registration desk helping with on-site registration and distributing name tags to attendees.

Fan Chen also helped Lizhen Gui collect course evaluation forms throughout the meeting.

Drs. Fan Chen and Xiaoping Sun were the official photographers and took numerous memorable and professional photos during the 2-day meeting.

Mark Liu spent a tremendous amount of his time in the weeks prior to the meeting comparing and contrasting local restaurants and selecting the best one for the Saturday night dinner party and social event. The environment was great, and the food was delicious! Everything was perfect!



The first CAPA Diagnostic Pathology Course Photographed by Xiaoping Sun (Cont'd on Page 3)



# The CAPA Annual Report 2015-2016 (Cont'd)

(Cont'd from Page 2)

The “tea party” at the home of Dr. Rouqing Huang brought additional fun, excitement, and social networking opportunities for many DuoTou and CAPA members. Wholehearted thanks for your hospitality!

## **B. Special Section for the Archives of Pathology & Lab**

### **Med**

Dr. Philip Cagle (editor-in-chief) and the Editorial Board of the *Archives of Pathology and Laboratory Medicine* invited CAPA to contribute a special section of up to 10 review articles to highlight the lectures presented at the first CAPA Diagnostic Pathology Course in NYC. Drs. Fan Lin and Lanjing Zhang are leading the project. All speakers have agreed to contribute to this very exciting endeavor. Manuscripts are expected to be completed by the end of the May 2016. The publication date will be determined by the Editorial Board of the *Archives*.

## **C. The First CAPA-Beijing Diagnostic Pathology Course**

The First Sino-US Cancer Diagnostic Pathology Summit was successfully held from October 16 to 18 in Beijing. The more than 400 attendees included numerous pathology departmental chairs and professors from well-known medical colleges and hospitals in China. The conference was organized by Dr. Ning Lu, professor and chair of the Pathology Department, National Cancer Institute and Hospital, Chinese Academy of Medical Sciences, and co-organized by Drs. Ximing Yang and Fan Lin of CAPA. The feedback and comments from the meeting organizers, speakers and, most importantly, the attendees, were extremely positive, and the meeting organizers have already begun to prepare for the second conference in 2016! Congratulations and thanks to all CAPA speakers for a job well done! Thank you for making CAPA more visible in China's pathology community! Eight lectures were presented by 7 CAPA speakers as listed below.

Please also refer to the conference summary in Chinese written by Professor Jianmin Ying published in the CAPA eNewsletter (issue #3, 2015).

- Quality Management of IHC – Zongming Chen
- Quality Improvement and Clinical Application for NGS and SNP Microarray in Solid Tumors – Hui Chen

- Select Topics on Pancreatobiliary Tumors—IHC Approach – Haiyan Liu (prepared by Fan Lin)
- Practical IHC in GU Pathology—A Morphologic and IHC Approach – Ximing Yang
- Immunohistochemical Surrogates for Molecular Classification of Breast Carcinoma, a 2015 Update – Ping Tang
- Immunohistochemical Analysis of Spindle Cell Tumors in the Skin – Hong Wu
- Diagnosis of Undifferentiated Carcinoma Using Immunohistochemical and Molecular Approach – Haiyan Liu
- Recent Advances in IHC and Genomics of Bladder Urothelial Carcinoma – Charles Guo

## **D. Participation in the AP-IAP Meeting in Australia**

Dr. Jim Zhai successfully organized the Head and Neck Pathology Long course at the 9th Asia Pacific International Academy of Pathology (APIAP) Congress at Brisbane, Australia. June 4, 2015.

The Speakers and topics were as following:

- Haodong Xu: What is new is HPV-associated squamous cell carcinoma?
- Jim Zhai: Practical approach to salivary glands tumors
- Yun Gong: Traps and Tips in FNA Diagnosis of Thyroid Bed.

Dr. Ming Zhou and Dr. Jim Zhai (Course co-directors) organized the Short Course on Frozen Section at the 9th Asia Pacific IAP Congress, Brisbane Australia. June 4-7, 2015

The speakers and topics were as following:

- Jim Zhai: The common pitfalls and challenges in frozen section diagnosis in head and neck
- Ming Zhou: The common pitfalls and challenges in frozen section diagnosis in genitourinary system
- Huamin Wang: The common pitfalls and challenges in frozen section diagnosis in pancreaticobiliary system
- Longwen Chen: The common pitfalls and challenges in frozen section diagnosis in gynecologic system
- Jing Zhang: The common pitfalls and challenges in frozen section diagnosis in neuropathology



The First CAPA-Beijing Diagnostic Pathology Course (Cont'd on Page 4)



# The CAPA Annual Report 2015-2016 (Cont'd)

(Cont'd from Page 3)

## E. Participation in the CSP 2015 Annual Meeting in Kunming

The 21<sup>st</sup> Congress of the CSP was successfully held from November 5 to 8 in Kunming, Yunnan Province. It was attended by over 1500 registered attendees. One factor contributing to the success of this meeting was the collaboration between CAPA leadership and CSP leadership by including a group of excellent speakers from among CAPA members. The CAPA speaker team was led by Drs. Marilyn Bui, Yun Gong and Beiyun Chen. Each team leader was in charge of one area, with Dr. Yun Gong - oral presentation, Dr. Beiyun Chen - subspecialty training, and Dr. Marilyn Bui - case presentation.

The speakers and topics were as follows:

- Peng Lee: Molecular Pathology in Genitourinary Cancers and a case presentation.
- Jingmei Lin: Pathologist's essential role in small bowel and multivisceral transplantation.
- Dongfeng Tan: Pathology Laboratory Tests for DNA Mismatch Repair Deficiency and Its Use in Cancer Precision Medicine.
- Xinmin Zhang: Molecular Tests for Cytologically Indeterminate Thyroid Lesions: the value and the limitations and a case presentation.
- Guoping Cai: Endoscopic Ultrasound-guided Fine Needle Aspiration Diagnosis of Pancreatic Lesions.
- Pen Lin: Diagnosis and Treatment of Anaplastic Large Cell Lymphoma in the Era of Immunotherapy and Targeted therapy.
- He Wang: Salivary gland fine needle aspiration.
- Yun Gong: Algorithmic approach to FNA diagnosis
- Yihong Wang: Tumor Infiltrating Lymphocytes in Breast Cancer and its Clinical Implication and a case report of a rare Adenoid Cystic Carcinoma of the Breast
- Shaoying Li: DLBCL Risk Stratification: Role of MYC and BCL2 cytogenetic status vs Protein Expression by Immunohistochemistry.
- Pifu Luo: Cytopathological Approach for Rapid and Accurate Intraoperative Diagnosis.
- Hua Yang: Prognostic and predictive markers of breast cancer and a case presentation.
- Beiyun Chen: Mimics of invasive breast carcinomas.
- Marilyn Bui: 1) A Practical, Multidisciplinary and Algorithmic Approach to Diagnose Bone and Soft Tissue Tumors; 2) Digital Pathology in Surgical Pathology: An Overview and Update; 3) PRKCB Immunohistochemical Stain Is a Novel Reliable

Diagnostic Biomarker of Ewing Sarcoma, and a case presentation.

## F. The First CAPA Companion Meeting at the CAP 2016 Annual Meeting

Dr. Lanjing Zhang's proposal to hold the first CAPA Companion Meeting at CAP Annual Meeting has been reviewed and approved by Dr. Cagle and the Committee. This was great news and another milestone for CAPA! CAPA will gain further acceptance by mainstream pathologists and have an opportunity to offer pathology courses to all potential CAP meeting attendees. The 2.0 hour (CME credits offered) companion meeting will take place in Las Vegas Saturday, September 24, from 4:00 to 6:00 pm. Drs. Lanjing Zhang and Huamin Wang and the organizing committee are working on the topics and speakers for this very exciting event!

## 3. CAPA eNewsletters and Website

The publication of the quarterly CAPA eNewsletters is another milestone. The eNewsletters have been well accepted and very effectively keep all members updated with CAPA news, upcoming events and activities, achievements from its members, networks with other pathology societies, and acknowledgements of contributors and sponsors. Drs. Huan - You Wang, Jun Zhang, Fan Chen and the Publication Subcommittee have led this project. Very special thanks to Dr. Fan Chen for her passion, talent, dedication and tireless effort to keep the CAPA eNewsletters published as scheduled.

The CAPA website has been updated with news and announcements in a very timely manner. We would like to acknowledge Dr. Jie Song's talent and contributions to the website. It has been very active with an over 10 folds of increases in the website traffics in the past 10 years.

## 4. Membership

The successful future of the CAPA is largely relied on the growth CAPA members. And the membership committee, led by Dr. Lizhen Gui, has done extremely well in recruiting new members and lifetime members. There are 510 CAPA members now. In 2015, over 70 new members were recruited; and also there are near 50 new lifetime members (most of them are previously regular members). The CAPA membership database has been refined and restructured. It has been proposed to have three categories of members: 1) lifetime member who paid a lifetime membership due; 2) regular member who pays a membership due on a yearly basis; 3) and associate member who does not pay a membership due but interested in being included in the CAPA mailing list. A unique member ID was issued to lifetime members and regular members who are eligible to join CAPA elections (pending from the approval of the bylaws changes). The member ID for each member will be used as a special identification number during the next CAPA officials' election in 2017, which will improve and ensure an unquestionable and unbiased election process.

## 5. Finance

2015 marked a year of successful financial reform in the CAPA's history. In March, a 5-person subcommittee, led by Dr. Zongming Chen, was formally established to manage

(Cont'd on Page 5)



International Academy of Pathology (APIAP) Congress at Brisbane, Australia. From Left to right: Drs. Jing Zhang, Jim Zhai, Ming Zhou, Linda Shen (Australian IAP), Huamin Wang, Longwen Chen, and Honggang Liu (Head and Neck pathologist in Beijing).



# The CAPA Annual Report 2015-2016 (Cont'd)

(Cont'd from Page 4)

CAPA's finance as a group. It is composed of the current president, the current and past treasurers, the membership subcommittee chairman and a liaison officer (Drs. Fan Lin, Zongming Chen, Fang Fan, Lizhen Gui, and Huihong Xu, respectively). Teaming with the Executive Committee, it accomplished four major goals:

- 1) Improving pre-existing account managing mechanism to enhance operability, transparency and leadership supervision;
- 2) Completing an auditing process with the professional help to ensure compliance with governmental regulations and safeguard CAPA's long term financial stability and growth;
- 3) Standardizing the vendor/sponsorship soliciting form to actively seek financial support;
- 4) Establishing an active monitoring mechanism to ensure accountability of all activities involving member engagement and contribution.

2015 also marked a year of the fastest financial growth in the CAPA's history. The following table lists the most important numbers reflecting its financial performance when compared to 2014.

Revenue, Cost and Net gain	2015
Income from members (membership dues, registrations, donations)	\$46396 (900% increase)
Income from sponsors (14 different companies/entities)	\$40500 (400% increase)
Total expenses (meeting costs, awards, and others)	\$57209 (500% increase)
<b>Net gain</b>	<b>\$29687 (600% increase)</b>

Looking forward into 2016, CAPA has planned many exciting events/activities to serve its members, all of which need more financial support. Building on the organization's reserve, CAPA has already secured a significant amount of additional sponsorship pledges in a new round of solicitation, which is not included in the net gain session of the table above.

## 6. Sponsors for CAPA Activities in 2015-2016

As the above financial report shows, CAPA has had a stronger and healthier financial year than ever, which enabled us to carry out the many successful activities reported above. Very special thanks to the following sponsors (in alphabetical order) for their very generous sponsorships and contributions to CAPA and CAPA activities!

- **Advanced Cell Diagnostics, Inc.**
- **American Society of Clinical Pathology**
- **BioGenex**
- **Cell Marque**
- **Dian Diagnostics**
- **Foundation Medicine**
- **Geisinger IHC Reference Lab**
- **Gopath**
- **Kingmed**
- **Maixin**
- **Motic**

- **NovoDix, Inc.**
- **Roche/Ventana**
- **Roche Diagnostics China**
- **Rosetta Genomics**

## 7. CAPA Awards

### CAPA Honorary Award and CAPA Member of the Year Award

Two new CAPA Awards have been created this year: the CAPA Honorary Award and the CAPA Member of the Year Award.

The CAPA Honorary Award was created to recognize a person (CAPA member or non-member) who has made a significant contribution to CAPA. The first Honorary Award will go to Dr. Philip Cagle. Dr. Cagle is the Editor-in-Chief for the *Archives of Pathology and Laboratory Medicine* and a professor of pathology at Methodist Hospital/Cornell Medical College. He has helped CAPA achieve two impressive milestones: 1) he approved the proposal for an *Archives* special section to publish the review articles from the first CAPA Diagnostic Pathology Course; and 2) he approved the proposal for the first CAPA Companion Meeting at the 2016 CAP Annual Meeting. CAPA is very fortunate to have such strong support from Dr. Cagle! Congratulations to Dr. Cagle!



**The CAPA Member of the Year Award** was created to recognize the CAPA members who have gone above and beyond to help CAPA achieve its ambitious goals. Without their passion, talent, effort, and dedication to this community, these challenging goals would have not been accomplished.

This year, this award will go to (in alphabetical order):

Drs. Fan Chen, Zongming Chen, Lizhen Gui, Ruoqing Huang, Huihong Xu, and Lanjing Zhang. Congratulations to the winners!




Fan Chen



Zongming Chen




Lizhen Gui



Ruoqing Huang



Huihong Xu



Lanjing Zhang

(Cont'd from Page 6)



# The CAPA Annual Report 2015-2016 (Cont'd)


(Cont'd from Page 5)

## Zu-Hua Gao Outstanding Service Award


Dr. Marilyn Bui is the winner of this traditional award. She is the chair of the CAPA Education Subcommittee for 2015-2016 and was a key organizer, speaker and moderator for the first CAPA Diagnostic Pathology Course in NYC. She led the CAPA speaker team and presented at the CSP Annual Meeting in Kunming, China. She has been very effectively soliciting for CAPA and successfully obtained sponsors for CAPA. Congratulations to Dr. Bui!



## CAPA-ACD Distinguished Pathologist Award



Drs. Jinsong Liu and Hanlin Wang are the recipients of this CAPA award. They are well-known in the CAPA community and long-time supporters of and contributors to CAPA. Both



are very successful in academic achievements. Congratulations to Drs. Liu and Wang!

## CAPA-Motic Best Abstracts Award

### First Place Prize

- ◆ A new variant of phosphaturic mesenchymal tumor exclusively involving alveolarbone: a clinicopathological analysis of 17 cases

Huanwen Wu et al. Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China.

### Second Place Prize

- ◆ Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma

Shi-Xun Lu, et al. Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China

- ◆ MicroRNA expression of Peripheral T and NK cell lymphomas in one hospital

Lin Feng, et al. State Key Laboratory of Molecular Oncology, Department of Etiology and Carcinogenesis, Cancer Hospital and Institute, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

### Third Place Prize

- ◆ Parameters associated with recurrence of pT1N0 esophageal squamous cell carcinoma after radical esophagectomy

Liyan Xue, et al. Department of Pathology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

- ◆ High Risk HPV Testing and Report Rate: Result from the Largest CAP Certified Independent Laboratory in China

Baowen Zheng, et al. Guangzhou Kingmed Diagnostics, Guangzhou, Guangdong

- ◆ Endocervical curettage should be performed in women older than 35 with cytological high-grade squamous intraepithelial lesions or carcinomas regardless of colposcopy impression

Yan Song, et al. Department of Pathology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

## CAPA-GoPath Best Abstract Award

### First Place Prize

- ◆ Wei Wang, et al. MD Anderson. Risk stratification of additional chromosomal changes in chronic myelogenous leukemia in era of tyrosine kinase inhibitor therapy

### Second Place Prize

- ◆ Hongyan Dai, et al. University of Kansas. miR-139 in breast cancer tumors and serum a surrogate marker for tumor aggression

- ◆ Qingqing Liu, et al. University of Massachusetts. Hemizygous deletion of RB1 gene in chromophobe renal cell carcinoma and its potential role in distinguishing chromophobe renal cell carcinoma from renal oncocytoma

### Third Place Prize

- ◆ Jinhua Piao, et al. St. Louis University. Vasodilator stimulated phosphoprotein (VASP) immunoreactivity is associated with lymphovascular invasion of colorectal adenocarcinoma (CRC) leading to liver and lymph node metastases

- ◆ Wendi Zhou, et al. University of California at Los Angeles. Diagnostic utility of clusterin immunostaining in differentiating hepatocellular carcinoma from tumors of other origins

- ◆ Bing Ren, et al. University of Pittsburgh. Programmed death ligand-1 (PD-L1) expression in mismatch repair deficient gastric tumors and gastric tumors positive for Epstein-Barr virus


In summary, the CAPA community is well-prepared and positioned for future growth. It has been my immense privilege to be a member of this great pathology community and, once again, I am honored to have had the opportunity to serve as its President in 2015! My professional life has been greatly enriched, inspired, and influenced by the many friends and colleagues I have met along the way, especially those with whom I have had close interactions during the last year. You are the best! I am grateful to the CAPA EC, Subcommittee chairs and co-chairs, Subcommittee members, and all the members and volunteers who worked closely with me to accomplish these ambitious goals. Together, we did it! Once again, I sincerely appreciate all sponsors for their very generous support. Finally, I strongly encourage all of you to be volunteers and more actively involved in all CAPA activities, now and in the future, because this is OUR OWN pathology community! Now Dr. Huamin Wang and the entire CAPA leadership team will take the CAPA to the next level. Together, we will build a stronger CAPA!

Respectfully submitted,

Fan Lin, MD, PhD  
CAPA President, 2015-2016



## Introducing CAPA Pathologists/Scientists



Dr. Jing Zhang (MD, PhD), Professor of Pathology and Adjunct Professor of Neurology, Ophthalmology, and Oral Health Sciences at the University of Washington (UW) School of Medicine in Seattle, Washington, currently serves as the Director of the Neuropathology Division of UW Medicine and the permanent holder of the Shaw Endowed Chair. More recently, he took over the

leadership of the Pathology Department affiliated with Peking University Health Science Center as well as Peking University Third Hospital. Dr. Zhang received his initial undergraduate and medical training in Shanghai, China, at the Second Military Medical College. After graduating from a PhD program in Cell Biology at Duke University in 1995, he finished his medical residency and fellowship in Anatomic Pathology and Neuropathology, respectively, at Vanderbilt University in 2001. Currently, Dr. Zhang is a practicing neuropathologist and ocular pathologist at UW Medicine and affiliated hospitals. Aside from his clinical duties, Dr. Zhang also leads a research team that is focused on neurodegenerative disorders, specifically Parkinson's disease and Alzheimer's disease. He is particularly interested in translational medicine, with a major emphasis on biomarker discovery and validation. His work typically involves collaborations with multiple medical centers, sometimes internationally. In 2007, Dr. Zhang won the Alzheimer's Award for his work in proteomics investigation of biomarkers in human cerebrospinal fluid. Dr. Zhang also has interests in molecular mechanisms, particularly in regards to mitochondrial dysfunction, oxidative stress, and neuroinflammation related to Parkinson's development and progression. He has been a principal investigator and beneficiary of multiple grants awarded by the NIH and various foundations for many years (2-3 millions/year on average since about 8 years ago). Dr. Zhang has also trained many young investigators, pre-doc, post-doc fellows, and junior faculty members; many of whom have now become independent investigators. Dr. Zhang has published about 200 SCI papers, with over 10,000 citations, and holds an H-Index of 55 as of January, 2016. More details on his research can be found in his website: <http://www.pathology.washington.edu/research/labs/zhang/>



Dr. Youli Zu (祖幼立) graduated from Jilin Medical College in China, and received his PhD degree from Kyoto University School of Medicine in Japan. Subsequently, he performed biomedical research at the University of Connecticut Health Center as an instructor/assistant professor. For continuing medical education, Dr. Zu completed Pathology residency training at New York University Medical Center and also finished Hematopathology fellowship training at the National Cancer Institute of the National Institutes of Health (NIH). In 2004, Dr. Zu joined the Baylor College of Medicine and Houston Methodist Hospital. Currently, he is a Professor at the Weill Medical College of Cornell University and the Medical Director of the Hematopathology Section, Department of Pathology and Genomic Medicine at Houston Methodist Hospital. In addition to his clinical responsibilities, Dr. Zu is also the Director of the Cancer Pathology research laboratory at Houston Methodist Research Institute. These combined positions enable him to apply his research findings to directly address clinical questions.

Dr. Zu is a pioneer researcher in developing clinical applications of the aptamer technology. Aptamers are a class of small-molecule ligands composed of short RNA or ssDNA. Similar to protein antibodies, oligonucleotide aptamers specifically recognize and bind to their targets with high affinity based on their unique three-dimensional structures. As "chemical antibodies", aptamers offer several advantages for clinical use because they can be easily synthesized and chemically conjugated to various diagnostic and/or therapeutic agents, and possess capacity for fast cell binding and deep tissue penetration. Dr. Zu's lab has previously developed multiple aptamers specific for different cancers and demonstrated the utility of aptamer technology for flow cytometric analysis, immunostaining of fixed tissues, detection of circulating tumor cells, *in vivo* tumor-specific imaging, nanomedicine production, targeted cancer therapy, and cancer immunotherapy. As PI/Co-PI, Dr. Zu is currently funded by multiple research grants, including NIH R01, R21, R33, and R41, and CPRIT grants from Cancer Prevention and Research Institute of Texas.

## CAPA Participation of CSP 2015

*(Cont'd from Page 1)*

One contributing factor to the success of this meeting is the collaboration between CAPA leadership and the CSP leadership by including a group of excellent speakers from CAPA membership. The CAPA speakers would like to take this opportunity to thank the CSP meeting organizing committee for their gracious acceptance of our presentation proposals and their kindly hospitality in Kunming. The junior members of the speakers especially appreciate the wonderful opportunity to be able to share the stage with many senior Chinese pathologists. Both the CAPA and CSP leadership are pleased with the result and will continue this collaboration. The next CSP meeting is going to take place in 合肥 (date to be determined, late Oct or early Nov, 2016). The CAPA leadership will send out the "Call for Speakers" to all CAPA members when CSP meeting organizers forward us the information.

The CAPA education committee would also like to thank the following speakers presented at CSP meeting and represented CAPA very well, led by group leaders Dr. Yun Gong (oral presentation), Dr. Beiyun Chen (Subspecialty training), and Dr. Marilyn Bui (Case presentation).

Peng Lee, New York University, Molecular Pathology in Genitourinary Cancers and a case presentation.

Jingmei Lin, Indiana University, Pathologists's essential role in small bowel and multivisceral transplantation.

Dongfeng Tan MD Anderson Cancer Center, Pathology Laboratory Tests for DNA Mismatch Repair Deficiency and Its Use in Cancer Precision Medicine.

*(Cont'd from Page 8)*



## CAPA Participation of CSP 2015

(Cont'd from Page 7)

Xinmin Zhang, Temple University, Molecular Tests for Cytologically Indeterminate Thyroid Lesions: the value and the limitations and a case presentation.

Guoping Cai, Yale University, Endoscopic Ultrasound-guided Fine Needle Aspiration Diagnosis of Pancreatic Lesions.

Pen Lin, MD Anderson Cancer Center, Diagnosis and Treatment of Anaplastic Large Cell Lymphoma in the Era of Immunotherapy and Targeted therapy.

He Wang, Temple University, Salivary gland fine needle aspiration.

Yun Gong, MD Anderson Cancer Center, Algorithmic approach to FNA diagnosis

Yihong Wang, Rhode Island Hospital, Tumor Infiltrating Lymphocytes in Breast Cancer and its Clinical Implication and a case report of a rare Adenoid Cystic Carcinoma of the Breast

Shaoying Li, MD Anderson Cancer Center, DLBCL Risk Stratification: Role of MYC and BCL2 cytogenetic status vs Protein Expression by Immunohistochemistry.

Pifu Luo, Providence Medford Medical Center, Cytopathological Approach for Rapid and Accurate Intraoperative Diagnosis.

Hua Yang, prognostic and predictive markers of breast cancer and a case presentation.

Beiyun Chen, Mayo Clinic, Mimics of invasive breast carcinomas.

Marilyn Bui, Moffitt Cancer Center, A Practical, Multidisciplinary and Algorithmic Approach to Diagnose Bone and Soft Tissue Tumors, Digital Pathology in Surgical Pathology: An Overview and Update, PRKCB Immunohistochemical Stain Is a Novel Reliable Diagnostic Biomarker of Ewing Sarcoma, and a case presentation.

## CAPA ACKNOWLEDGES THE FOLLOWING SPONSORS FOR THEIR SUPPORT

Advanced Cell Diagnostics, Inc.  
 American Society of Clinical Pathology  
 BioGenex  
 Cell Marque  
 Dian Diagnostics  
 Foundation Medicine  
 Geisinger IHC Reference Lab  
 Gopath  
 Kingmed  
 Maixin  
 Motic  
 NovoDiox, Inc.  
 Roche/Ventana  
 Roche Diagnostics China  
 Rosetta Genomics

**MXB**  
biotechnologies

**Maixin provides comprehensive range of solutions for immunohistochemistry**

**Biotechnologies**  
福州迈新生物技术开发有限公司  
☎ : 400-8889-853/800-8881-156

Stains are a good thing ...  
Quality stains are our thing

**Geisinger**

Please stop by and see Geisinger IHC at the USCAP 2016 Annual Meeting in Seattle from March 14 - 16 at booth #538.

geisingerihc.com

**10 MINUTE** INTRAOPERATIVE **DIRECT IHC**

Time In Minute	Procedure
0-5	Fixation
0-1	Wash in PBS
0	No Blocking
5	PolyHRP-Antibody
0-4	Wash in Water
1	DAB
0-1	Wash in Water
2-3	Counter Staining + Dehydration + Coverslipping
<b>9-10</b>	<b>Total Time</b>

**Available Products:**

- ihcDirect AE1/AE3
- ihcDirect Mart-1
- ihcDirect CK8/18
- ihcDirect Synaptophysin
- ihcDirect Herceptin

**NOVODIAX**

VISIT [www.novodiox.com](http://www.novodiox.com)  
 CALL 1.888.439.2716  
 EMAIL [novoinfo@novodiox.com](mailto:novoinfo@novodiox.com)




# CAPA ACKNOWLEDGES THE FOLLOWING SPONSORS FOR THEIR SUPPORT

**No antibody.  
No problem.**

Breakthrough multiplex RNA *in situ* hybridization for any gene with RNAscope® technology.

Because up to 76% of protein-coding genes have no reliable antibody for immunohistochemistry (IHC), your research often comes to a screeching halt while you wait for a new antibody to be developed. With rapid probe design and universal assay workflows for any gene, RNAscope® technology frees you from the hassles of antibody screening, saving you precious time and effort, while driving publication quality data.

Learn more about RNAscope® Technology at [www.acdbio.com](http://www.acdbio.com)



**ACD**  
Advanced Cell Diagnostics

For Research Use Only. Not for diagnostic use. RNAscope is a registered trademark of Advanced Cell Diagnostics, Inc. in the United States or other countries. All rights reserved. ©2015 Advanced Cell Diagnostics, Inc.

## Rare for you but not for Foundation Medicine

RARE/UNCOMMON SUBTYPE	PERTINENT TUMOR DRIVER	FDA APPROVED TARGETED THERAPIES	FDA APPROVED THERAPIES IN ANOTHER TUMOR TYPE
Non-Serous Ovarian Cancer, e.g. Ovarian Clear cell	BRCA1/2	Olaparib	Trastuzumab, Pembrolizumab
	ERBB2		Paclitaxel, Carboplatin
	FRR1/2/3		Temozolomide, Everolimus
	AKT1/2		Olaparib and others
Pancreaticobiliary Cancers: Cholangiocarcinoma Pancreas Cysticobiliary	IGH1/2		Azacitidine, Decitabine
	ERBB2		Trastuzumab, Pertuzumab, ADAM12
	FGFR2		Patupilone
	BRAF		Dabrafenib, Trametinib, Vemurafenib
	PTEN		Everolimus
	BRCA2		Trastuzumab, Pembrolizumab
	ERBB2		Trastuzumab, Pembrolizumab
Uncommon subtypes of breast cancer	CENPA	Palbociclib	Trastuzumab, Pertuzumab
	BRCA1/2		Olaparib
	ESRR		Abiraterol, Casuzumab
	ERBB2		Erlotinib, Lapatinib, Pembrolizumab, Trastuzumab
	PIK3R, NF1, STK11, ARID1A, PTEN		Everolimus, Tansartan
Salivary Gland	ERBB2		Trastuzumab, Pembrolizumab
	ESRR		Carotumab, Lapatinib
	PTEN		Tansartan, Everolimus
	BRCA1/2		Olaparib
	BRAF		Trametinib, Dabrafenib

Comprehensive genomic profiling using FoundationOne has been performed on > 16,000 uncommon tumor cases. Learn more at: [USCAP Annual Meeting Booth #541](http://USCAP Annual Meeting Booth #541)

**FOUNDATION MEDICINE**

## BioGenex

**Game Changer**



Integrated eFISHiency System

- FISH Probes
- Detection Systems
- Smart Automation  
Hands-On Time < 30 min.  
Up to 10 protocols per run

**miRNA In Situ - Dawn of a New Era**


**For Clinical Research & Tumour Analysis:**

- Cancer of Unknown Primary
- Undifferentiated Tumors
- Cancer Staging




**Xmatrix<sup>TM</sup> NANO**

**Xmatrix<sup>TM</sup> ELITE-INFINITY and NANO miRNA-ISH Automation**



**Broadest portfolio of FDA-cleared image analysis algorithms with the VENTANA Digital Pathology Solution**



■ER ■PR ■HER2 ■Ki-67 ■p53

VENTANA and the VENTANA logo are trademarks of Roche.  
© 2015 Roche Diagnostics Corporation  
9115 Hague Road • PO Box 50414 • Indianapolis, IN 46250

Digital Scanner and Telepathology Platform  
Automated Cervical Cancer Screening  
Cancer DNA Ploidy Analysis  
Cytology and Surgical Pathology Services



美克奥迪(厦门)医疗诊断系统有限公司  
MOTIC (XIAMEN) MEDICAL DIAGNOSTIC SYSTEM CO., LTD.

厦门美克奥迪医学检验所  
XIAMEN MOTIC MEDICAL LABORATORY

**数字病理远程会诊平台**  
[www.moticpathology.com](http://www.moticpathology.com)

Motic Medical Diagnostic Systems, Xiamen, China  
[med.motic.com](http://med.motic.com)